Radiopharmaceutical · Cytotoxic, directed at somatostatin receptor 2 (SSTR2) · developed by Perspective Therapeutics
VMT-α-NET is a radiolabeled agent, given as lead-203 for SPECT imaging and as lead-212 for treatment, that targets SSTR2-expressing tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05636618 | Phase 1/2 | Neuroendocrine Tumors Unresectable | Recruiting | CATX |
| NCT06148636 | Early Phase 1 | Neuroendocrine Tumors | Active not recruiting | CATX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Bronchial Neuroendocrine TumorGastroenteropancreatic Neuroendocrine TumorMeningiomaNeuroendocrine Tumor Grade 1Neuroendocrine Tumor Grade 2Neuroendocrine Tumor MetastaticNeuroendocrine Tumor of PancreasNeuroendocrine Tumor of the LungNeuroendocrine TumorsNeuroendocrine Tumors UnresectableParagangliomaPheochromocytoma
Updated Oct 11, 2026. Something wrong or missing? Report it on the CATX page.
See CATX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CATX catalysts and pipeline →